Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALT
Strong SellSinkerAltimmune, Inc. · Healthcare · United States · $605M · Avg Vol: $15M/d
COMPANY DESCRIPTION
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel peptide-based therapeutics for chronic diseases, with a primary focus on obesity and liver diseases. The company's pipeline includes differentiated candidates like pemvidutide, a GLP-1/glucagon receptor dual agonist, aiming to address significant unmet medical needs. Its competitive value is intrinsically tied to the clinical efficacy and market potential of its proprietary drug candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -68.0K | 0.4M | 20.0K | 41.0K | -69.0% | 31.0K | 4.1K | — | -90.0% |
| EPS | -0.46 | -0.60 | -0.50 | -1.00 | — | -0.76 | -0.59 | -0.67 | — |
| Shares | 194.5M | 194.5M | 194.5M | 110.9M | -43.0% | — | — | — | — |
| Debt | 1.1M | 0.7M | 1.7M | 35.7M | 216.7% | 36.0M | — | — | — |
| Equity | 185.3M | 194.1M | 123.5M | 224.9M | 6.7% | — | — | — | — |
| Op CF | -62.6M | -75.8M | -79.8M | -67.5M | — | -76.5M | — | — | — |
| Inv CF | -73.4M | 13.7M | -28.4M | -132.5M | — | — | — | — | — |
| Fin CF | 56.8M | 86.1M | 10.0M | 206.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALT | Altimmune, Inc.(you) | $605M | 16 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 17 | Strong Sell |
| ZURA | Zura Bio Limited | $548M | 19 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $485M | 15 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $743M | 14 | Strong Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 22 | Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $699M | 12 | Strong Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 22 | Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%